Press Releases

2010 | 2009 | 2008 | 2007 | 2006
Keyword Search
 
DateTitle
11/24/08Covidien and Depomed Announce License Agreement
11/21/08Depomed, Inc. Announces Conference Call to Discuss Exclusive North American License Agreement with Solvay Pharmaceuticals, Inc.
11/20/08Depomed, Inc. Announces Exclusive North American License Agreement with Solvay Pharmaceuticals, Inc. for DM-1796 (Gabapentin GR(R) in the Treatment of Pain
10/30/08Depomed Reports Third Quarter 2008 Financial Results
10/24/08Depomed To Present at Three Upcoming Conferences
10/20/08Depomed Initiates Second Phase 3 Trial in Menopausal Hot Flashes
10/16/08Depomed to Announce Third Quarter 2008 Financial Results on October 30, 2008
09/25/08Depomed Announces Presentation of Clinical Data at the North American Menopause Society Annual Meeting
09/18/08Depomed to Present at the UBS Global Life Sciences Conference
09/17/08Depomed Initiates Phase 3 Program in Menopausal Hot Flashes
07/31/08Depomed Reports Second Quarter 2008 Financial Results
07/23/08The Michael J. Fox Foundation Awards Depomed a Preclinical Development Grant for Levodopa/Carbidopa in Parkinson's Disease
07/23/08Depomed's ProQuin(R) XR Achieves First Marketing Authorization in Europe
07/22/08Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
07/17/08Depomed to Announce Second Quarter 2008 Financial Results on July 31, 2008
07/09/08Depomed Achieves Tier 2 Reimbursement Status for Glumetza(R) With CVS Caremark
06/30/08Depomed Secures $15 Million in Non-Dilutive Funding for Hot Flash Program
06/17/08Depomed Announces Allowance of Additional U.S. Patent Covering Gabapentin GR(R)
05/30/08Depomed to Present at the 7th Annual Needham & Co. Biotechnology & Medical Technology Conference
05/01/08Depomed Reports First Quarter 2008 Financial Results
04/24/08Depomed to Announce First Quarter 2008 Financial Results on May 1, 2008
04/08/08Depomed Elects Karen A. Dawes to Board of Directors
04/07/08Depomed Settles Patent Litigation Against IVAX
03/24/08Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
03/06/08Depomed Reports Preliminary 2007 Year End Financial Results
02/25/08Depomed to Announce Fourth Quarter and Year-End 2007 Financial Results on March 6, 2008
02/20/08Depomed Names Abid Rawn Vice President of Sales and Marketing
02/12/08Depomed Reports Positive Efficacy Data From a Phase 2 Trial of Gabapentin GR(TM) in the Treatment of Menopausal Hot Flashes
02/05/08Depomed to Present at the BIO CEO & Investor Conference
01/02/08Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza